Roche-Hansoh deal illustrates China’s growing role as source of new drugs
Roche’s pact with Hansoh underscores China’s growing importance in supplying experimental medicines, supported by rapid development and greater trust in its science. Hansoh will receive $400 million upfront and $110 million...To view the full article, register now.
Already a subscriber? Click here to view full article